[Intrathecal chemotherapy in acute lymphoblastic leukemia. Prospective evaluation of toxicity using a combination employed in Mexico].
Gómez-Almaguer
D
D
Almaguer-Gaona
C
C
Mora-Brondo
P
P
González-Llano
O
O
Marfil-Rivera
J
J
Villarreal
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007278:Injections, Spinal; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011446:Prospective Studies; D014839:Vomiting / Q000139:chemically induced
D003561:Cytarabine; D003907:Dexamethasone; D008727:Methotrexate
Quimioterapia intratecal en leucemia aguda linfoblástica. Evaluación prospectiva de la toxicidad utilizando una combinación recomendable en México.